SOLIRIS / ULTOMIRIS REFERRAL FORM		SUPERIOR BIOLOGICS Fax Referral To: 914-747-1170				
Date: Pho			ne: 855-747-11	50		
Patient Information           Patient Name:			Prescriber Information         Prescriber Name:			
Primary Insurance:				ID#:       Group:         ID#:       Group:		
Secondary Insurance: Prescription Card: ID#:					#: Group:	
<ul> <li>New to Therapy Currently on Therapy Date of Last IVIG Infusion: IVIG Dosing Regimen:</li> <li>Diagnosis: G70.00 Myasthenia Gravis without (acute) exacerbation G70.01 Myasthenia Gravis with (acute) exacerbation in crisis</li> <li>D59.3 atypical Hemolytic Uremic Syndrome (aHUS) D59.5 PNH G36.0 Neuromyelitis Optica Date of Diagnosis:</li> <li>Weight: Patient Date: Allergies: Date of MenACWY: Date of MenB:</li> <li>Previously on PLEX treatment DYes DNo Date of last treatment: Is patient AchR antibody positive? DYes DNo</li> <li>Is the Patient Anti-Aquaporin-4 (AQP4) antibody positive? DYes DNo Notes/Comments:</li> </ul>						
Soliris (eculizumab) Ultomiris (ravulizumab)						
Strength Directions			Strength Directions			
Injection: 300mg / 30mL (10mg/mL) in a single-dose vial Anaphylaxis Orders Diphenhydramine Adm Epinephrine Autoinjecto Sodium Chloride 0.9% (	<ul> <li>For treatment of Myasthenia Gravis:</li> <li>900mg weekly for the first 4 weeks, followed by 1200mg for the fifth dose 1 week later, ther</li> <li>1200mg every 2 weeks thereafter.</li> <li>For treatment of aHUS – 18 years or older:</li> <li>900mg weekly for the first 4 weeks, followed b</li> <li>1200mg for the fifth dose 1 week later, then</li> <li>1200mg every 2 weeks thereafter.</li> <li>For treatment of NMOSD:</li> <li>900mg weekly for the first 4 weeks, followed b</li> <li>1200mg for the fifth dose 1 week later, then</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>1200mg weekly for the first 4 weeks, followed b</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>600mg weekly for the first 4 weeks, followed b</li> <li>900mg or the fifth dose 1 week later, then</li> <li>1200mg for the fifth dose 1 week later, then</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>1200mg or the fifth dose 1 week later, then</li> <li>900mg every 2 weeks thereafter.</li> </ul>		Injection: 300mg/30mL (10mg/mL) in a single dose via 300mg/3 mL (100mg/mL) in single dose via 1,100mg/mL) in single dose via 1,100mg/mL) in single dose via * Do not mix ULTOMIF mg/mL (3mL and 11ml and 10mg/mL (30mL v concentrations togeth **When switching therapy Ultomiris loading dose sho given at the time of next scheduled Soliris dose. P pens) is Dispense: QS	A For treatm based at t 40kg): A B B For treatm weeks a a For treatment treatment bial CRS 100 CRS 100 Cher: V Access Flush Order: NaCl0.9% 5-10ml/V before a	eent of Myasthenia Gravis - weight time of treatment (patient must be at least ing as a single dose, followed by ing once every 8 weeks later starting 2 after the loading dose. eent of aHUS – weight based at time of : _mg as a single dose, followed by _mg once every (4 or 8) weeks later g 2 weeks after the loading dose. eent of PNH – weight based at time of _mg as a single dose, followed by _mg once every (4 or 8) weeks later g 2 weeks after the loading dose.	
Quantity Refills						
Other/Notes: Prescriber Signature: DAW (Dispense as Written)						

The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intend recipient, please notify us immediately.